Chugai Pharmaceutical Co., Ltd.
Research Chugai Pharmaceutical Co., Ltd. (CUP0) on Bullrun: valuation model: 2.2% overvalued, market cap EUR 65.17B, P/E 27.5, dividend yield 3.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCUP0
- ExchangeF
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Valuation signal2.2% overvalued
- Market capEUR 65.17B
- P/E27.5
- Dividend yield3.9%
- Financial periodFY2025
- RevenueEUR 1.26T
- Revenue growth7.5%
- Free cash flowEUR 274.67B
- Gross margin71.1%
Valuation Snapshot
Bullrun's latest valuation model marks Chugai Pharmaceutical Co., Ltd. as 2.2% overvalued; latest market cap is EUR 65.17B; P/E is 27.5; dividend yield is 3.9%.
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant;
Frequently asked questions
Is Chugai Pharmaceutical Co., Ltd. overvalued or undervalued?
Bullrun's valuation model currently marks Chugai Pharmaceutical Co., Ltd. as 2.2% overvalued.
What is Chugai Pharmaceutical Co., Ltd.'s market cap?
Chugai Pharmaceutical Co., Ltd.'s market capitalization is EUR 65.17B.
What is Chugai Pharmaceutical Co., Ltd.'s P/E ratio?
Chugai Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 27.5.
Does Chugai Pharmaceutical Co., Ltd. pay a dividend?
Chugai Pharmaceutical Co., Ltd. has a dividend yield of 3.9%.
What does Chugai Pharmaceutical Co., Ltd. do?
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.